Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A rearrange |
Therapy | Fingolimod |
Indication/Tumor Type | acute lymphoblastic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Fingolimod | Preclinical - Cell culture | Actionable | In a preclinical study, Gilenya (fingolimod) inhibited proliferation and induced cell death and cell cycle arrest in an acute lymphoblastic leukemia cell line harboring KMT2A rearrangement in culture (PMID: 37891368). | 37891368 |
PubMed Id | Reference Title | Details |
---|---|---|
(37891368) | SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML. | Full reference... |